Evidence map›Paper›PMID 29456160›Full record

ArticleThe Lancet. Neurology2018

Hypercholinergic activity in LRRK2 Parkinson's disease.

Nicolaas I Bohnen, Roger L Albin

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet. Neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. The Cholinergic Brain in Parkinson's Disease.Movement disorders clinical practice · 2021
    Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Nicolaas I BohnenDepartment of Radiology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA; University of Michigan Udall Center and VA Ann Arbor Healthcare System, Ann Arbor, MI, USA. Electronic address: nbohnen@umich.edu.
Roger L AlbinDepartment of Neurology, University of Michigan, Ann Arbor, MI 48109, USA; University of Michigan Udall Center and VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.

Funding

Public Outreach and Education CoreP50NS091856 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ALBIN, ROGER L · 2014 to 2019
$10.1M
NINDS NIH HHS P50 NS091856
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Parkinson DiseaseCholinergic AgentsCross-Sectional StudiesHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MutationCholinergic AgentsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, human

Identifiers

PMID29456160
PMCPMC5858987

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.